RETHINKING DIABETES CARE IN CANADA: EARLIER ACHIEVEMENT OF COMPREHENSIVE TREATMENT GOALS FOR PEOPLE WITH TYPE 2 DIABETES WITH DUAL GIP/GLP-1 RECEPTOR AGONISM (AS-107)

Thursday, October 26, 2023

12:30 – 13:30 EST

Location: Palais, 517A

Target Audience: Endocrinologists, Diabetologists, Family Physicians, Residents, Allied Health Professionals

Chair : AS(s)

Akshay Jain, MD, FRCPC, FACE, CCD, ECNU, DABOM

Staff Endocrinologist
TLC Diabetes and Endocrinology
University of British Columbia

Presenter : AS(s)

JL

Julie Lovshin

University of Toronto
Lori Berard

Nurse Consultant
Independent
RG

Robbie Goldberg
DN

Daniel Ngui, BScPT, MD, FCFP

Clinical Associate Professor, UBC Dept of Family Medicine, Medical Director Fraser Street Medical
University of British Columbia

Disclosure(s):

Akshay Jain, MD, FRCPC, FACE, CCD, ECNU, DABOM: Abbott: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); Amgen: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); Astra Zeneca: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Bausch Healthcare: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Bayer: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Boehringer Ingelheim: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Dexcom: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Diabetes Canada: Speaker/Honoraria (Ongoing); Eli Lilly: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); HLS Therapeutics: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Insulet: Consultant/Advisory Board (Ongoing); Novo Nordisk: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); PocketPills: Consultant/Advisory Board (Ongoing); Timed Right: Speaker/Honoraria (Ongoing)

Lori Berard: ABBOTT Diabetes Care: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Bayer: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Convatec: Consultant/Advisory Board (Ongoing); DexCOM: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Eli Lilly: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Embecta: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); HLS: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Novo Nordisk: Speaker/Honoraria (Ongoing); Sanofi: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Vertex: Consultant/Advisory Board (Ongoing)

Learning Objectives / Objectifs d'apprentissage:

At the end of this session participants will be able to / Au terme de cette conférence, vous serez:

gain an understanding of the potential mechanisms of action of GIP/GLP-1 receptor agonist therapy;
explore the benefits of achieving early glucose control and weight reduction on preserving the long-term health of people living with type 2 diabetes;
review the efficacy, safety, and tolerability data of GIP/GLP-1 receptor agonist therapy for patients living with type 2 diabetes; and
identify patients who could benefit from GIP/GLP-1 receptor agonist therapy.

This program was co-developed by the Canadian Society of Endocrinology and Metabolism and Eli Lilly Canada and was planned to achieve scientific integrity, objectivity, and balance.